[News] Dosimetric promise versus cost: critics question proton therapy

20:41 EDT 27 Jun 2013 | The Lancet

Already the global leader in proton beam therapy centres, the USA is expected to see a rapid proliferation of these expensive facilities in the near future. However, amid growing calls for health-care cost control, critics contend that proton centres...

Original Article: [News] Dosimetric promise versus cost: critics question proton therapy

NEXT ARTICLE

More From BioPortfolio on "[News] Dosimetric promise versus cost: critics question proton therapy"

Search BioPortfolio:
Loading
Advertisement
Advertisement

Searches Linking to this Story